drugset
Drugs / BMS-214662
last change Sep 2005 re-read 2 minutes ago

BMS-214662

also known as NSC 710086 · NSC 710086D

Small molecule

Developed for
cancer of unknown primary site · acute promyelocytic leukemia · adult acute lymphoblastic leukemia · blast phase chronic myelogenous leukemia, BCR-ABL1 positive · childhood acute lymphoblastic leukemia · childhood acute myeloid leukemia · childhood malignant neoplasm · childhood myelodysplastic syndrome
+2 more · myelodysplastic syndrome with excess blasts · refractory anemia with excess blasts in transformation
Investigated by
National Cancer Institute (NCI) · Case Comprehensive Cancer Center · Memorial Sloan Kettering Cancer Center

Trials 6 · a red edge is where a trial was stopped

today NCT00022529 · Ph 1 NCT00006018 · Ph 1 NCT00006242 · Ph 1 NCT00005973 · Ph 1 NCT00006213 · Ph 1 NCT00004877 · Ph 1
19992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT00022529 Jul 2001 → Jan 2004 cancer of unknown primary site National Cancer Institute (NCI) Completed No outcome recorded
Phase 1 NCT00006018 Jul 2000 → Dec 2001 cancer of unknown primary site Case Comprehensive Cancer Center Completed No outcome recorded
Phase 1 NCT00006242 Jul 2000 → Sep 2005 cancer of unknown primary site National Cancer Institute (NCI) Completed No outcome recorded
Phase 1 NCT00005973 Apr 2000 → Jul 2004 cancer of unknown primary site, childhood malignant neoplasm National Cancer Institute (NCI) Completed No outcome recorded
Phase 1 NCT00006213 Apr 2000 → Oct 2002 acute promyelocytic leukemia, adult acute lymphoblastic leukemia, blast phase chronic myelogenous leukemia, BCR-ABL1 positive, childhood acute lymphoblastic leukemia +4 National Cancer Institute (NCI) Completed No outcome recorded
Phase 1 NCT00004877 Jul 1999 → Apr 2001 cancer of unknown primary site Memorial Sloan Kettering Cancer Center Completed No outcome recorded

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 7 sources stand behind the page.

FieldValueCited text
Known as BMS-214662 ClinicalTrials.gov intervention name — accepted as the source's own label NCT00006213 ↗
5

NCT00004877 ↗

NCT00006242 ↗

NCT00006018 ↗

NCT00022529 ↗

NCT00005973 ↗
Known as NSC 710086 “A Phase I Trial of Farnesyltransferase Inhibitor BMS-214662 (NSC 710086) Escalating to a 24 Hour Continuous Intravenous Infusion in Patients With Solid Tumors” NCT00006242 ↗
Known as NSC 710086D “Phase I Study of Farnesyl Transferase Inhibitor BMS-214662 (NSC 710086D) in Solid Tumors” NCT00005973 ↗
Action Inhibit “Farnesyl Transferase Inhibitor BMS-214662” NCT00005973 ↗
Modality Small molecule — CHEMBL351706 ↗
Route Intravenous “Patients receive BMS-214662 IV over 1 hour on day -7” NCT00004877 ↗